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3Abstrakti
Parkinsonin-tauti on yleisin liikehäiriösairaus, jonka esiintyvyys yli 60 vuoden
ikäisessä väestössä on noin 1%. Parkinsonin-taudin syy on tuntematon mutta
useita elämäntapoihin ja ympäristötekijöihin liittyviä riskitekijöitä tunnetaan.
Todennäköisesti myös perinnölliset tekijät vaikuttavat sporadisenkin
Parkinsonin-taudin riskiin.
Korkean plasman uraatti-pitoisuuden on havaittu vähentävän riskiä sairastua
Parkinsonin-tautiin ja myös hidastavan motoristen oireiden etenemistä taudin
puhjettua. Väitöskirjan hypoteesina oli että Parkinsonin-tautia sairastavilla olisi
matalampi plasman uraatti-pitoisuus kuin terveillä puoliso-verrokeilla ja että
matala uraatti-pitoisuus altistaisi potilaita neurokognitiivisille ja
neurofysiologisille muutoksille seuranta-aikana.
Plasman uraatti mitattiin 40 potilaalta ja 28 terveeltä puoliso-verrokilta.
Potilaille tehtiin neuropsykologinen tutkimus, joka toistettiin 3 vuoden
seurannan jälkeen. 18 potilaalta ja 24 verrokilta rekisteröitiin aivosähkökäyrä,
jonka yhteydessä mitattiin kuulo-herätevasteita. Tämän neurofysiologisen
tutkimuksen tarkoituksena oli selvittää eroavaisivatko potilaiden ja verrokkien
herätevasteet toisistaan ja vaikuttaisivatko Parkinsonin-taudin aiheuttamat
neurokognitiiviset muutokset herätevasteiden havaitsemiseen.
Tutkimuksessa osoitettiin että Parkinsonin-tautia sairastavilla on merkittävästi
matalammat plasman uraatti-pitoisuudet kuin verrokeilla. Potilailla matala
plasman ja vuorokausivirtsan uraatti assosioituivat alentuneeseen
tarkkaavuuteen ja toiminnanohjaukseen ja vaikeuksiin näönvaraisessa
hahmottamisessa.
Kolmen vuoden seuranta-aikana potilaiden kognitiivisessa tilanteessa ei
tapahtunut merkittäviä muutoksia. Kognitio ei myöskään vaikuttanut
assosioituvan uraatti-tasoihin enää seuranta-ajan lopussa.
Herätevaste-tutkimuksessa havaittiin, että Parkinsonin-tautia sairastavilla N100-
vasteen latenssi oli pidempi ja vasteen habituaatio heikompi kuin verrokeilla.
Nämä muutokset korreloivat neuropsykologisessa tutkimuksessa havaittuun
näönvaraisen työmuistin heikentymiseen mutta eivät plasman tai virtsan uraatti-
pitoisuuteen.
4Abstract
Parkinson’s disease (PD) is the most common movement disorder, affecting
approximately 1% of the population aged over 60 years. According to current
knowledge, there are both genetic and environmental risk factors for this
disease. High plasma uric acid level has been shown to reduce the risk of PD
and also to decelerate the progression of motor symptoms in patients with PD.
In this study, 40 PD patients and 28 spouse controls were recruited to examine
whether patients have low plasma and daily urine uric acid levels relative to the
controls. Also neuropsychological testing was performed on patients both at
baseline and after three years of follow-up to determine whether cognition is
associated with the uric acid levels and whether low levels of uric acid at
baseline predict future cognitive decline.  An electroencephalogram with
evoked response potentials (EEG-ERP) was given to a subsample of patients
and controls to examine neurophysiological differences between the groups and
to investigate whether cognitive alterations are reflected in patients’ EEG-ERP
measurements.
PD patients had lower levels of plasma uric acid than controls. Low plasma and
urine uric acid levels were associated with poor achievement in
neuropsychological tests measuring visuospatial and visuoconstructive abilities,
sustaining attention and executive control. After three years of follow-up, only
minor cognitive decline was noted in patients. Cognition did not seem to be
associated with past or present uric acid levels.  On the other hand, the stability
of the patient sample made it difficult to assess the effect of uric acid on the
prognosis of cognitive decline in PD.
The EEG-ERP study revealed that PD patients had longer latency and poorer
habituation of the evoked response potential N100 than healthy controls. In the
patient group, the neurophysiological changes were associated with poor
achievement in a neuropsychological test measuring visual working memory,
but not with uric acid levels.
5Introduction
Parkinson’s disease (PD) is a complex neurodegenerative disorder with multiple
symptoms from a wide area of the central nervous system.
The common age of onset is above 50 years, but especially the rare genetic
forms and also sporadic PD may begin earlier. The motor symptoms of PD
comprise slowness of movement, muscle rigidity and resting tremor. This
classic triad, having regularly an asymmetrical onset, forms the cornerstone of
the diagnosis, which is still mainly based on clinical examination. According to
clinico-pathological studies, the accuracy of the diagnosis is approximately
75%1. Computed tomography (CT) and magnetic resonance imaging (MRI) are
useful only to rule out other causes such as vascular lesions and tumours.
The motor symptoms of PD were long considered to constitute the major burden
of the disease. However, the non-motor symptoms often have an enormous
impact on the quality of life. Diminished or absent sense of smell, REM sleep
behaviour disorder and constipation are early signs of PD and may precede the
occurrence of motor symptoms by years2. Later on, facial expressions are
diminished, the voice becomes forceless and dysarthria may develop, with
devastating social consequences. The architecture of sleep is often fragmented,
forcing patients to wake up several times during the night or to wake up early
without being able to fall back asleep. Bladder frequency typically increases and
nocturia may add to sleep disturbance. Orthostatic hypotension and balance
problems produce falls and hinder the patients’ willingness to move, thus
adding to disability3.
The most devastating consequence is cognitive decline and ensuing Parkinson’s
disease dementia (PDD), which cause a gradual loss of independence and
usually a substantial caregiver burden. The cognitive symptoms have insidious
onset and the episodic memory often remains spared for a long time. The
common first symptoms are slowness of thought, word finding difficulty and
visual and executive dysfunction. Working memory is often disturbed, but more
profound amnestic syndrome usually develops later4-6.
There are currently numerous pharmacological and neurosurgical treatments
available for the motor symptoms, but few for cognitive decline. Dementia also
limits the use of PD medicines to treat the motor symptoms, as hallucinations
and even psychoses may develop as side effects. Also neurosurgical
interventions are not possible with PDD. In view of these limitations, it is easy
to see why identification of treatable risk factors for cognitive decline in PD is
6imperative. Emerging treatment options also prompt the need for diagnostic
tools to detect cognitive decline and dementia in PD.
In humans, uric acid is the end product of purine metabolism7. The level of uric
acid in the plasma/serum varies according to body mass index (BMI) and
genetic and dietary factors, animal proteins contributing significantly to the
level of purines available to uric acid synthesis8. Below is a picture of the
metabolic pathway of uric acid. In other mammals, uric acid is further degraded
to allantoin, but humans have lost the uricase enzyme during evolution. This
may have even contributed to the long life span of humans since uric acid’s
antioxidative qualities may function as a preservative that makes tissues more
tolerant to oxidative stress and ageing.
GMP=guanosine monophosphate
AMP=adenosine monophosphate
7Uric acid is a powerful antioxidant and iron binding protein, making it an
intriguing research subject in neurological diseases such as PD, where oxidative
stress and locally increased iron level seem to play an active part. In
epidemiological studies, a high level of serum uric acid has been found to
reduce the risk of PD. In early PD, uric acid has been observed to attenuate the
progression of both motor symptoms and nigral cell damage, with uric acid thus
being the first recognized molecule to slow disease progression in PD9.
Little data exist on serum uric acid levels in PD patients or its effect on non-
motor symptoms such as cognitive decline. Given the lack of treatments to alter
the disease course and the high prevalence of cognitive symptoms in PD, this
thesis aimed to investigate whether patients with PD have low plasma uric acid
levels and whether uric acid contributes to cognition in PD. In the future,
increasing the plasma uric acid level might be a therapeutic option to slow the
progression of both motor and cognitive symptoms in PD.
8Review of the literature
Key epidemiological findings
In 1981, Ames et al. presented a novel hypothesis of uric acid, arguing that it
would provide an antioxidant defence in humans against oxidant- and radical-
caused ageing and cancer10.  As oxidative stress has long been considered one
of the mechanisms of cellular damage in PD, it was plausible to assume that a
high serum uric acid level would protect from PD.  To test this hypothesis,
Davis et al. conducted a prospective study among 8006 men of Japanese or
Okinawan ancestry, who participated in the Honolulu Heart Program. The
principal aim of the Honolulu Heart Program was to examine whether
Westernization would have an impact on cardiovascular morbidity and
mortality. As uric acid is a risk factor for cardiovascular disease, it was also
measured at baseline. The cohort was prospectively followed for 30 years,
during which time 92 new cases of PD were observed. Only the diagnoses made
by a neurologist or a neurosurgeon were included in the study. Men with above
median serum uric acid had a 30% reduction in the risk of PD11.  This finding
gained little interest in the research community until de Lau et al. reported
similar findings from a large, population-based cohort from the Netherlands in
2005. The study population included 4695 participants, both men and women,
aged 55 years or older. Subjects with PD or signs of parkinsonism at baseline
were excluded. Serum uric acid was measured at baseline and the cohort was
repeatedly screened for signs of PD in a standardized fashion for over 9 years.
During follow-up 68 new cases of PD were identified.  Cox proportional
hazards model showed a significant reduction in the risk of PD with increasing
serum uric acid concentration. The risk reduction seemed to be equally strong in
both men and women12.
There are also patient populations suffering from long-term hyperuricemia, a
state of abnormally high serum uric acid level, causing gouty arthritis. Gout is a
metabolic disorder that is characterized by increased serum uric acid level and
deposition of urate crystals in joints and kidneys, causing acute painful arthritis
and kidney stones. One would expect that the long-term hyperuricemia in gout
would lead to a reduced risk of PD.  There are several studies examining this
association, but the findings have been contradictory. While some studies have
shown an approximately 30% reduction in the risk of PD13-15, others have found
no association16,17. Most studies have been registry-based and have used the
prescription of anti-gout medication as a proxy for the diagnosis of gout. Even
when a diagnosis of gout was mandatory in the study protocol, the diagnostic
criteria applied had not been explicitly defined. This variation in the case
ascertainment may explain some of the contradictory findings. As with uric
acid, some studies have found gout protective of PD in men only, which may
also be a source of bias in these studies.
9Lifestyle factors and risk of PD, a link to uric acid?
Milk and dairy products
Consumption of milk and dairy products has been found to increase the risk of
PD 18. This association has been observed in both men and women. Drinking
milk in adulthood is common in Finland, and a positive association between
milk and PD also emerged in a Finnish study by Sääksjärvi et al.19
 At first, it was speculated that milk and dairy products might contain
contaminants, such as pesticides, from cows’ feed. This hypothesis was
strengthened by a recent study measuring the neuronal density of substantia
nigra in healthy postmortem brains20. An intake of milk exceeding 16 oz (263
ml) daily was associated with a 40% reduction in neuron density. The reason for
this remained obscure, but there were also traces of heptachlor epoxide in the
brain slices. This pesticide was previously found in milk in the area where the
study subjects lived and where the milk was produced. Exposure to pesticides is
a known risk factor of PD, but increased risk in association with heptachlor
epoxide has not been shown.
Our study group has presented an alternative hypothesis of an association
between milk and serum uric acid levels. Milk is known to decrease serum uric
acid levels, probably by increasing the excretion of uric acid in the kidneys.
Daily consumption of milk and dairy products has also been shown to decrease
serum uric acid levels in a large epidemiological study including 14 809
participants21. Regular intake of milk and dairy products might therefore
decrease the serum uric acid levels and predispose to PD. This hypothesis was
also considered more likely in a recent review22.
Weight loss
Weight loss is also associated with low levels of serum uric acid, and gradual
loss of weight increases the risk of PD. This was found in the Harvard Alumni
Health Study, comprising 12 228 men, 88.4% of whom had adhered to the study
until the end of follow-up. Eventually, 106 men were diagnosed with PD. Men
losing 0.5 units of body mass index per decade had a 2.6 multivariate relative
risk of PD23. Unexplained weight loss is common in PD, and this finding may
reflect the long prodromal period of PD24.
Caffeine
The role of caffeine in PD has long puzzled neurologists. Whether caffeine
protects from PD was prospectively examined in the Honolulu Heart Program
described earlier. Coffee drinkers had a significantly lower incidence of PD than
non-drinkers. For those who did not consume coffee at all, the risk for PD was
10
2-3 times higher25. This finding has since been replicated by others, and there is
also a Finnish study on the subject. This population-based study included 6710
Finns, with an extensive follow-up of 22 years. During this time 101 incident
cases of PD occurred. After adjusting for various potential confounders, the
heavy coffee drinkers were found to have a 0.26 relative risk of PD compared
with non-drinkers26.
The most likely explanation for this association is caffeine’s function as an
adenosine A2a-receptor antagonist27. Adenosine A2a-receptors and dopamine
D2-receptors interact in the substantia nigra, and blocking of the adenosine
A2a-receptors increases the level of available dopamine. This provides
symptomatic relief in PD.  In the cellular models of PD, caffeine has prevented
neuronal death induced by MTPT, a finding that is also mediated by the
adenosine A2a-receptor28. Apparently, adenosine receptor antagonism reduces
glutamate-mediated toxicity in the substantia nigra and reduces the
inflammatory actions of glial cells, which also express these receptors.
Our group has proposed an additional mechanism of caffeine’s neuroprotective
action.  Molecularly, caffeine is a purine alkaloid that metabolizes in the body
to form theobromine and xanthine, both having strong antioxidant capacity29
and structural similarity to uric acid. Xanthine also metabolizes further to
produce uric acid. We have therefore suggested that regular caffeine
consumption would reflect years of self-administered antioxidant intake.
Tea
While the protective effect of coffee has been attributed to caffeine, there is
another component in tea that seems to provide an equal benefit. Drinking tea
has been shown to reduce the risk of PD, and this risk reduction was first
assumed to be caused by caffeine in tea. In the Singapore Chinese Health Study,
the authors were able to show that black tea was associated with reduced risk of
PD and that the risk reduction was independent of caffeine30. In this study, the
oestrogen levels were highest in the drinkers of black tea. As both exogenous
and endogenous oestrogens seem to reduce the risk of PD, the authors suggested
that some ingredient of tea might operate through an oestrogen-mediated
mechanism. There is also evidence of antioxidant capacity in both green and
black tea extracts, though the biological significance in humans is uncertain.
In addition to the other antioxidants, tea is known to contain small amounts of
methylxanthine, known as theophylline in pharmacology. Theophylline
resembles caffeine in that both are purine alkaloids and adenosine receptor
antagonists. Xanthine is also a precursor of uric acid, and the methylated form
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may either mimic the action of uric acid or increase its serum levels, although
this has not been shown. The protective effect of tea may therefore be mediated
by a mechanism similar to that of uric acid.
The structural similarity of uric acid, xanthine, caffeine, theophylline and
theobromine can be seen in the pictures showing their respective molecular
structures.
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Other factors related to risk of PD
In addition to the lifestyle factors presented above, there are other known
modifiers of the risk of PD.
Smoking tobacco has been found to decrease the risk of PD by up to 70% with
increased duration of smoking 31,32. It was previously suspected that the
association between smoking and PD risk might be explained by certain
personality traits of people prone to have PD. These individuals would be risk-
aversive and less sensation-seeking, and perhaps their dopamine metabolism
would be altered in a way that would make them less prone to addictions.  In
light of the accumulating epidemiological evidence, this theory has been
abandoned. The protective effect of tobacco is most likely mediated by nicotine,
and animal studies also favour this hypothesis33. The effect of some other, yet
unrecognized substances in tobacco cannot be ruled out. A randomized trial
using a transdermal nicotine patch in patients with early PD is ongoing
(NCT01560754).
Physical activity during adolescence and adulthood carries a decreased risk of
PD in later life34,35. The explanation for this epidemiological finding is not
known, but physical activity has been suggested to protect neurons by
regulating dopamine turnover36, increasing the release of neurotrophic factors37
and increasing serum uric acid38.
Regular use of non-steroidal anti-inflammatory drugs, especially ibuprofen,
reduces the risk of PD39. This finding is probably explained by the anti-
inflammatory action that supresses the microglia’s inflammatory response.
Regular use of calcium-channel blockers that are commonly used to treat
hypertension also reduces the risk of PD40. The mechanism of the possible
neuroprotective action of these drugs is probably a blockade of calcium
channel-mediated metabolic stress on mitochondria of the dopaminergic
neurons. Because of this scientifically acceptable explanation and a known
safety profile, isradipine is currently being investigated in treatment of early PD
(NCT02168842).
Alcohol also offers a slight decrease in the risk of PD when comparing drinkers
and non-drinkers. This may also be explained by the uric acid-elevating
qualities of alcohol41.
Exposure to pesticides is related to increased risk of PD42. The evidence for this
comes from agricultural studies, where farm work explains long-term exposure.
Although no specific compound has been recognized as a major risk factor, the
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ones that cause a defect of mitochondrial complex I or oxidative stress seem the
likeliest candidates.
Genetic factors
The serum uric acid levels depend on weight and diet, but there is also genetic
variability. Gonzalez-Aramburu et al. conducted a large study on 1061 PD
patients and 754 normal controls. They analysed polymorphisms in 9 genes
known to regulate serum uric acid levels and found that having 9 or more
polymorphisms that decreased the level of uric acid increased the risk of PD
1.5-fold. This association was found in both men and women 43. In another
study recruiting early-stage PD patients from both the DATATOP and
PRECEPT study populations, the researchers analysed single-nucleotide
polymorphisms (SNPs) in the urate transporter SLC2A9 gene. This is the
strongest known genetic regulator of serum uric levels. The patients with SNPs
producing low serum uric acid levels had a greater risk of progression to
disability requiring levodopa therapy. They also had significantly lower levels
of serum uric acid than the patients without these SNPs 44.
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Pathogenesis of PD
To find explanations for the view that uric acid might be neuroprotective in PD,
one must first look at the pathogenic mechanisms of the disease.
The neuropathology of PD involves the appearance of inclusion bodies in both
cellular processes and soma of neurons, called Lewy neurites and Lewy bodies,
respectively45. The Lewy neurites and Lewy bodies are composed of fibrillar,
phosphorylated alpha-synuclein, which has gone through a conformational
change into a beta-sheet, lost its membrane binding capacity and aggregated.
Normally, alpha-synuclein is present in various cell types and tissues. In the
brain, it is expressed in the presynaptic terminals of neurons. Its physiological
functions are not fully understood, but it most likely participates in regulating
vesicular release and synaptic plasticity as well as mitochondrial complex 1
activity. Alpha-synuclein is able to adopt different conformations to guide its
actions. This plasticity makes it vulnerable to changes in the cellular
environment, which may induce the formation of beta-sheet structure and
ensuing alpha-synuclein aggregation46.
Although Lewy bodies are the pathological hallmark of PD, it is not known
whether they are active participants in the pathological process of PD or
whether they are formed to sequester toxic, aggregated alpha-synuclein from
disturbing cellular homeostasis.
There are rare genetic forms of PD with overexpression of or mutations in the
alpha-synuclein gene SNCA. The clinical picture is often earlier onset and more
aggressive, but otherwise the symptoms and neuropathological findings bear a
close resemblance to the sporadic disease. The overexpression of alpha-
synuclein seems therefore sufficient to produce its aggregation and
neurodegeneration of dopaminergic neurons47. The mutations in the SNCA-gene
on the other hand stabilize beta-sheet structure and also promote aggregation. In
light of this, it seems likely that at least alpha-synuclein is an active player in
the pathogenesis of PD48.
The familial forms of PD are rare, and traditionally, the influence of genes has
been considered very low in sporadic PD. In twin studies, the hereditability of
PD has been low and concordance even in monozygotic twins has been no more
than 15%49. In Finland, Kuopio et al. studied familial occurrence of PD in a
community-based sample. The odds ratio of having a first-degree relative with
PD was 2.7 in patients compared with controls. The authors stated that this
finding may not be explained solely by genetic factors, but that shared
environmental risk factors may also contribute50.
The advent of genome-wide association (GWA) techniques may change our
views about the importance of genes in PD.  GWA studies have so far revealed
that although there are no high-risk alleles for PD, there are certain risk loci at
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the genes encoding both alpha-synuclein and microtubule-associated protein tau
(MAPT) as well as in the genes regulating membrane trafficking, endocytosis
and proteolysis. These findings point to there being some genetic background in
PD, although the genetic risk at the individual level is low and may require a
combination of several risk alleles as well as the presence of environmental or
lifestyle risk factors. The GWA studies also give important clues to the
pathogenesis. While overexpression of alpha-synuclein may be sufficient to
induce its oligomerization and aggregation, dysfunction of the protein
degradation pathways, such as proteolysis and lysosomal clearance, also
increase the level of alpha-synuclein51.
In humans, according to Braak52, the accumulation of alpha-synuclein starts in
the lower brain stem, especially in the dorsal motor nucleus of the vagal nerve
(DMV) and the olfactory system. From the lower brain stem, the alpha-
synucleinopathy then ascends from the DMV to the raphe nucleus, the reticular
formation and the locus coruleus.  Eventually, the disease process reaches the
neuromelanin-containing neurons of the substantia nigra and the patient enters a
symptomatic stage in which the first motor symptoms appear. The disease does
not remain confined to the substantia nigra, but ascends further and eventually
involves the whole brain. At the later stages, the Lewy bodies are also seen in
the neocortex.  Neural cell death is observed especially in the substantia nigra,
where the loss of pigmented, neuromelanin-containing dopaminergic neurons
leads to motor symptoms. Substantial neural cell death also occurs in the
nucleus basalis of Meynert, locus coruleus and raphe nucleus.
While the reason for the selective death of the dopaminergic neurons in PD is
unclear, multiple mechanisms of disease have been recognized. In addition to
alpha-synuclein aggregation, increased oxidative stress, activation of microglia
and ensuing neuroinflammation, dysfunction of mitochondrial complex 1,
accumulation of iron and dysfunction of protein degradation pathways all
contribute to the neurodegeneration in PD.
Microglia are the brain’s resident macrophages that sense changes in the
cellular environment and respond to them in an attempt to maintain cellular
homeostasis. The microglia also try to clear excess alpha-synuclein from the
extracellular space, but, due to alpha-synuclein toxicity, this leads to
proinflammatory changes and increased production of reactive oxygen species
(ROS) and increased oxidative stress53. Binding of soluble alpha-synuclein to
microglial membrane proteins also leads to activation of inflammatory
pathways that eventually induce a proinflammatory response also in the
astrocytes, further increasing the oxidative burden.
Alpha-synuclein affects mitochondrial membrane trafficking by inhibiting
protein import mechanisms and probably causing dysfunction of complex I,
although the data are not conclusive in this regard46. Dysfunction of
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mitochondrial complex I has been shown in PD, and it is known to lead to cell
death though the exact mechanism of this remains unknown54. Mitochondrial
dysfunction may also occur with ageing, as deletions of mitochondrial DNA
accumulate. Ageing may therefore increase the vulnerability of mitochondria to
alpha-synuclein toxicity. Dysfunctional mitochondria produce ROS and further
activate microglia. Also genetic studies point to the important role of
mitochondrial dysfunction in PD. Some genes identified in the hereditary forms
of PD, such as PINK1, LRRK2 and parkin, regulate the function of
mitochondria and increase the vulnerability of mitochondria to ROS55.
Increased load of alpha-synuclein also renders the dopaminergic cells
vulnerable to exogenous toxins. The pesticides used to mimic PD in animal
models of the disease are complex I inhibitors and their toxicity is aggravated
by alpha-synuclein.
Although alpha-synuclein accumulation, aggregation and ensuing toxicity are
important steps in the pathogenesis of PD, alpha-synuclein does not seem to be
the sole culprit.  The special features of dopamine metabolism suggest that its
alterations also contribute to the process.
 Dopamine degradation produces ROS, especially o–quinones, which are able to
damage mitochondria, induce alpha-synuclein aggregation, alter protein
degradation and increase oxidative stress55. Dopamine metabolism also requires
iron as a cofactor56. While iron is essential to the normal functioning of all cells,
an increased amount of unbound iron is highly toxic57. The iron content of the
brain tends to increase during normal ageing, but this process is accelerated in
PD, where iron accumulation has been found especially in the substantia nigra
without a corresponding increase in the level of iron binding proteins such as
ferritin54 or, more importantly, neuromelanin58.
The end-product of dopamine degradation is neuromelanin, an antioxidant and
iron-binding protein59,60, which is stored in dopaminergic neurons and gives
substantia nigra its dark colour. When released into extracellular space after
dopaminergic cell death, it induces an inflammatory reaction in the microglia.
In living cells, neuromelanin helps to contain the oxidative burden produced by
dopamine metabolism and is mainly responsible for sequestering free iron in the
substantia nigra. In PD, the iron binding capacity of neuromelanin saturates and
the pool of labile, unbound iron in nerve cells increases. The unbound iron
contributes to the neurodegeneration via Fenton reaction, which produces
cytotoxic hydroxyl radicals57,61, increases the level of oxidative stress and
promotes alpha-synuclein aggregation. Iron also interacts with the o-quinones to
increase the pro-oxidant burden in the PD brain 56.
An epidemiological finding of special interest is that melanoma predicts an
increased risk of PD62. The causal link has not been established, but melanin is
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an obvious common denominator. A genetic defect or dysfunction of the
melanin-related enzymes has been speculated to explain this association. Also
phosphorylated alpha-synuclein has been found to be enriched in cutaneous
malignant melanoma63. From these findings, it may be deduced that either there
is an underlying malfunction of the melanins or alpha-synuclein changes the
function of melanin in both melanoma and PD.
The pathogenic mechanisms described above form a vicious cycle which drives
the neurodegeneration in PD. What initially induces the neurodegenerative
process is still unclear, but research on the interplay of the intestine and brain
may provide additional clues.
It has long been recognized that there is some form of gastrointestinal
dysfunction in PD; chronic constipation is one of the strongest risk factors or
more likely a prodromal symptom of the disease. Slow gastric emptying and
decreased intestinal motility predispose PD patients to small intestine bacterial
overgrowth (SIBO), the prevalence of which has been found to be significantly
higher in PD patients than in normal controls (54% vs. 8%)64. In addition,
antimicrobial therapy has been reported to improve the motor symptoms in the
patients with SIBO65. Against this background, the novel hypothesis of gut-
originating, inflammation-driven PD presented by Houser et al.66 gives a new
perspective to the PD puzzle.
Houser et al. propose that the first step of PD is an inflammatory trigger
introduced in the gut. This may be a toxic substance, such as a pesticide, or an
infectious agent that provokes an intestinal inflammatory response. In some,
perhaps genetically susceptible individuals, this leads to chronic intestinal
inflammation, increased permeability of the gut wall and deleterious changes in
the microbial composition of the intestine.
Altered gut microbiota has been recently described in a Finnish study reporting
that in the faeces of PD patients the abundance of Prevottellaceae was reduced,
and, on the other hand, in those with postural instability and gait disturbance the
abundance of Enterobacteriacea was increased67. The authors suggested that gut
microbiota alteration may change the behaviour of enteric neurons and possibly
increase the secretion of alpha-synuclein. The vagal nerve would be a possible
pathway through which alpha-synuclein would then spread to the brain. In
support of this theory, alpha-synuclein has been found in the parasympathetic
intestinal plexuses of Meissner and Auerbach. Also a proof-of-concept study
was recently carried out where human alpha-synuclein was introduced to the rat
intestinal wall and later found in the brain stem68.
In the classical Braak’s model of PD neuropathology, DMV is the site of the
first appearance of alpha-synuclein. However, Braak’s model has been
challenged by Kalaitzakis et al., who noted that not all PD brains show alpha-
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synuclein pathology in DVM69. This contradicts the theory that the vagal nerve
plays an essential role in transferring noxious substances to the brain in PD. If
intestinal pathology has a role in PD, it seems to be more likely that the
inflammatory mediators leak from the damaged gut wall to provoke a systemic
immune response and damage the blood-brain barrier.  This eases the entrance
of the mediators of inflammation into the brain, where local microglia-driven
inflammation induces alpha-synuclein aggregation.  A study by Donadio et al.
demonstrated phosphorylated alpha-synuclein in skin-nerve biopsies in patients
with PD, thus favouring the systemic mechanism in the pathogenesis of PD70.
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Picture 1. Model of gut-originating, inflammation-driven PD pathogenesis.
Reprinted from the original article with the permission of Dr. Tansey.
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In summary, while multiple pathogenic mechanisms have been recognized in
PD and there is increasing evidence of their interplay at least in the brain and
probably also elsewhere in the body, the triggering event remains obscure. It
may be that the mechanism that has evolved to protect the brain from the
harmful by-products of dopamine metabolism fails due to genetic or
environmental factors or ageing, or more likely due to a combination of these
factors. There is also a possibility of an unrecognized exogenous trigger that
might be a neurotropic virus, toxic substance or even a prion-like protein that
provokes inflammation in the brain and possibly in the gut, increases the level
of alpha-synuclein in the intestine and peripheral and central nervous systems,
activates microglia and produces chronic inflammation in the brain. In
individuals with genetic susceptibility, age-related accumulation of mutations in
the mitochondrial genome and lifestyle factors predisposing to PD, the
inflammation accelerates oxidative stress, mitochondrial dysfunction and
accumulation of iron in the substantia nigra.
Uric acid in pathogenesis of PD
Low serum uric acid level is a risk factor for PD. A low level of uric acid may
be explained by genetic or dietary factors, BMI and possibly altered microbial
environment of the gut. Prevotella-dominated enterotype, rare in PD patients, is
associated with higher uric acid levels. The reason for this in not known, but
individuals with abundant Prevotella bacteria may have lower activity of
hydroxyl-isourate hydrolase, which catalyses intestinal uricolysis71. Prevotellae
also produce butyrate, a short-chain fatty acid that has anti-inflammatory
actions and this may also affect colonic uric acid level71. Currently, it is not
known whether the changed microbiota of the gut is a cause or a consequence of
PD. It may also be an unrelated chance finding. However, it is an intriguing
thought that changes in the gut microbiota would predispose to developing PD
also by reducing the brain’s antioxidant capacity by lowering uric acid levels.
This would also mean that individuals with genetically low plasma uric acid
levels would be more vulnerable to changes in the intestinal microenvironment.
 In PD, one of the central pathogenic mechanisms is oxidative stress, which is
partially a consequence of an increased pool of labile iron in the brain. The
neuroprotective action of uric acid has been attributed to its antioxidant and iron
binding capacity72-74. In dopaminergic cellular models, uric acid has prevented
oxidative stress and cell death caused by 6-hydroxydopamine, dopamine and
rotenone (a pesticide used to induce neuropathological changes similar to PD).
Uric acid is able to form stable complexes with iron ions, thus reducing the
toxicity of unbound iron72.  Serum uric acid and ferritin concentrations are
closely correlated75, which indicates common regulatory mechanisms of their
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production, and uric acid and ferritin have shared responsibilities in the human
body and brain75,76.
Uric acid also indirectly increases the antioxidant capacity of the brain by
regulating astrocytes via nuclear factor like 2 (Nrf2) pathway77. Nrf2
transcriptionally regulates the expression of gamma-glutamyl transferase, the
rate-limiting enzyme of glutathione synthesis. Glutathione is a powerful
antioxidant, which is released by astrocytes as a reaction to oxidative stress.
Astrocytes also express glutathione transferase, which catalyses glutathione
conjugation of the o-quinones into stable forms. This mechanism probably
protects both astrocytes and dopaminergic neurons from the oxidative by-
products of dopamine metabolism78.
In summary, uric acid seems to be a strong modifier of the risk of PD. Low
serum uric acid level, the cause of which may be genetic, dietary or possibly
related to altered gut microbiota, increases the risk of PD. A low level of serum
uric acid renders the brain more vulnerable to increased oxidative stress caused
by dopamine metabolism, alpha-synuclein aggregation, mitochondrial
dysfunction and neuroinflammation. The neuroprotection provided by uric acid
is probably mediated by the Nrf2 pathway, but uric acid’s direct antioxidant
function and iron binding capacity may also be important features.
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Recent clinical findings of uric acid in PD
The PRECEPT study recruited patients with early PD to investigate the effect of
an orally administered anti-apoptotic mixed lineage kinase inhibitor CEP-1347,
which was assumed to be neuroprotective based on animal data. The results
were not promising, but serum uric acid concentration was measured at baseline
in 806 PD patients and in the sub-analyses it appeared to predict clinical
outcome. The study subjects were followed up for an average of 21.4 months,
during which time 61% reached the primary end point of disability sufficient to
require dopaminergic therapy. The higher the uric acid level at baseline, the less
likely it was to reach this end point. The association was stronger in men than in
women.
Single-photon emission tomography of iodine I 123-labelled beta-CIT uptake
was available in 399 patients at both baseline and end of follow-up. The
progression of dopaminergic deficit was also slower with high serum uric acid
levels, and, again, the association was stronger in men. The authors concluded
that serum uric acid is the first molecular factor directly linked to the
progression of typical sporadic PD79.
 Later, the same researchers repeated their findings in another study that was
designed to determine whether serum and cerebrospinal fluid uric acid levels
would affect clinical progression of PD. The subjects were again people with
early PD and the primary end point was disability requiring levodopa therapy.
Higher serum and cerebrospinal fluid uric acid concentrations were associated
with slower rates of clinical decline79,80.
In their third study on the subject, the authors found that in patients with
parkinsonism who were included in the study as PD patients, the likelihood of
having a (123I)beta-cit SPECT without dopaminergic defect was higher those
with high serum uric acid concentrations81.
Increasing uric acid as a therapeutic strategy in PD
The promising data of the above-mentioned study inspired a trial to use inosine
to increase the serum uric acid levels in PD39. This phase II trial aimed to assess
safety and tolerability of serum uric acid elevation in early PD not yet requiring
symptomatic therapy.
Seventy-five patients with below population median serum uric acid levels were
recruited and randomized to either placebo or a low or high dose of inosine. The
patients with above population median serum uric acid levels were excluded
because the net benefit concerning the risk of progression might not be
significant in that patient group and also because they were considered more
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vulnerable to the possible adverse events caused by increased serum uric acid
concentration (gout, urolithiasis, renal disease and vascular events).
In the active treatment group, there was an increased number of urolithiasis
cases, but no serious adverse events associated with high serum uric acid
concentration occurred; blood pressure, BMI, serum glucose and cholesterol
levels remained the same throughout the study. In the study group, the serum
uric acid levels were significantly increased relative to placebo. Importantly,,
there was a trend towards slower progression of the disease in the active
treatment group. The study population was small and the follow-up short,
bearing in mind the slow progression of PD. However, the results concerning
safety and tolerability were promising. A phase 3 trial (NCT02642393) is now
ongoing to assess whether increasing serum uric acid levels with inosine might
decelerate the progression of motor symptoms in early PD. This randomized,
placebo-controlled, double-blind, multicentre trial is planned to last 2 years and
the main outcome variable is change in the Movement Disorder Society’s
Unified Parkinson’s Disease Rating Scale (MDS-UPDRS).
Cognitive decline in PD
Cognitive decline is one of the most devastating symptoms of PD. The studies
examining cognition in early, non-medicated PD are few but well conducted.
The estimations of the prevalence of mild cognitive impairment (PD-MCI) vary
in these studies, ranging between 18% and 34% 82 83 84. The variance is probably
due to differences in patient demographics and study designs. Moreover, the
diagnostic criteria for PD-MCI have not been consistent, but this problem will
probably be  mitigated in future studies that will hopefully follow the
Movement Disorder Society Task Force Guidelines to diagnose PD-MCI85.
The most common neuropsychological deficits in PD are found in the areas of
attention, verbal memory and fluency, psychomotor speed and visuospatial and
executive functions83,86-88. Once established, PD-MCI carries a poor prognosis
with further decline in cognition and subsequent development of PD-Dementia
(PDD)6. There are two quite recent studies on the evolution of cognitive decline
in early PD that follow the Movement Disorder Society Task Force Guidelines
to diagnose PD-MCI and PDD89.  Both of these have extensive follow-ups.
In the Norwegian Park-West Study, 182 patients were serially tested for
neuropsychological deficits at baseline and after 1 and 3 years.  Of the patients,
20.3% were considered to have PD-MCI at baseline, 27% of whom developed
PDD within 3 years of follow-up. The demented patients were older, less
educated and had longer disease duration and more severe motor symptoms of
PD than the non-demented group 90.
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In another study, 123 PD patients were examined at baseline. Due to drop-outs,
93 and 59 patients were available for follow-up at 3 and 5 years, respectively.
Altogether, 35% were found to have PD-MCI at baseline and 53% at 3 years. Of
the 59 patients who reached the final follow-up visit, 50% had PD-MCI and
34% PDD4.
The neuropathology of cognitive decline in PD includes degeneration of
subcortical nuclei with both neuronal loss and Lewy body pathology. The
magnitude of cell loss in the medial substantia nigra and ensuing dopaminergic
defect correlate with the severity of cognitive decline. Also locus coeruleus,
nucleus basalis of Meynert and dorsal raphe nucleus degenerate in most cases.
These nuclei have vast connections to cortical areas and their degeneration leads
to cortical noradrenergic, cholinergic and serotonergic defect, respectively91.
The ensuing corticostriatal dysfunction explains the clinical picture of
diminished attention, dysexecution, visuospatial problems and reduced working
memory capacity that are common in PD.
 Cortical Lewy body pathology as suggested by Braak is not always present
even in PDD, and, on the other hand, patients even in Braak stages 5-6 may not
have clinically defined dementia92. The major risk factor for cognitive decline
and dementia in PD is age93. While cognitive decline is not a part of normal
ageing, pathologies other than PD may accumulate over time. Concomitant
Alzheimer’s disease (AD) and cerebral vascular pathology lower the threshold
for the appearance of cognitive symptoms in PD. Genetic findings also
corroborate the hypothesis of multiple pathogenic mechanisms of cognitive
decline since PD patients with polymorphisms in cathecol-O-methyl-transferase
(COMT), microtubule-associated protein Tau (MAPT) and APOe have a
predilection for distinctive cognitive profiles94. COMT regulates the level of
cortical dopamine, MAPT regulates the folding of Tau-protein and APoe4
predisposes to AD dementia.
One must also bear in mind that there are protective factors, such as education
and physical activity, which may help to preserve cognition even in
neuropathologically advanced disease.
There is no reliable biomarker for the diagnosis of PD-MCI or PDD. In
neuroimaging studies, widespread hypometabolism has been described in
frontal, temporal, parietal and occipital cortical regions 95,96. In PDD, these
changes usually exceed the metabolic changes found in AD, reflecting a global
neurotransmitter deficit. Magnetic resonance imaging (MRI) studies have found
cortical atrophy in the same regions as well as hippocampal atrophy, although to
a lesser extent than in AD 9798.
PET imaging with Pittsburgh compound to detect cortical amyloid has also been
examined in PD. Interestingly the amyloid load is significantly lighter in PDD
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than in AD, and in cognitively normal PD it seems to be similar to that in
healthy controls 99. However, it has been hypothesized that even a low amyloid
burden would have a marked impact on cognition with coexisting PD. The
underlying neurodegenerative process makes the brain more vulnerable to
amyloid and ensuing memory problems. Interestingly, although neuropathology
in dementia with Lewy bodies is difficult to differentiate from PDD, there is a
higher prevalence of AD pathology in dementia with Lewy bodies100. Clinically,
dementia with Lewy bodies and PDD bear a close resemblance and their
differential diagnosis is rather arbitrarily defined by the sequence of the
occurrence of symptoms. If the cognitive symptoms precede the onset of the
motor symptoms by a year or more, the disease is called dementia with Lewy
bodies101. If the motor symptoms appear first with ensuing cognitive decline, the
disease is called PDD89. These two diagnoses have lately been considered to
represent the opposite ends of a disease spectrum and an umbrella term of Lewy
body dementias has been suggested to include both dementia with Lewy bodies
and PDD102. In my opinion, dementia with Lewy bodies may be seen as a very
late onset form of PD with coexisting AD pathology.
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Uric acid and cognition
While the neuroprotection offered by uric acid against developing PD and
progression of motor symptoms seems undisputable, the evidence concerning
cognition is contradictory.
As to the available literature, the first study assessing uric acid’s effect on
cognition was conducted in 2007 by Schretlen et al.103 In this community-based
study, 96 adults over 60 years of age and with no evidence of neurological
disease such as PD were examined. All of the study subjects had serum uric
acid levels within the reference range, but those with high-normal levels scored
poorly in tasks measuring verbal and working memory. This association
remained statistically significant even after controlling for several potential
confounders such as age, sex, education, diabetes, hypertension, smoking and
abuse of alcohol. The authors suggested that the detrimental effect of uric acid
on cognition might be mediated by cerebrovascular changes, as high serum uric
acid has been considered a vascular risk factor associated with diabetes,
hypertension and obesity.
Schretlen et al. tested their hypothesis in another community-based sample of
177 subjects aged 20-92 years. The amount of cortical and subcortical
hyperintense white matter lesions was evaluated from brain MRI scans and
these lesions were considered to be of vascular origin since patients with other
causes of white matter lesions, such as multiple sclerosis, were excluded. The
serum uric acid levels were within the reference range, but even a high-normal
uric acid level increased the likelihood of a heavy ischaemic burden up to 5-fold
in subjects aged 60 years and over.104 This finding was corroborated in the
Rotterdam Scan study, where white matter atrophy and worse cognition were
associated with hyperuricaemia in 814 people from a community sample105.
 Euser et al. conducted a large prospective community-based study including
4618 subjects aged 55 years or older to investigate the relationship between uric
acid and subsequent dementia. During the 10-year follow-up 457 subjects
developed dementia. Ten years after the baseline serum uric acid measurement,
the cognitive function was analysed in a subpopulation of 1724 subjects who
remained free of dementia. After carefully controlling for several vascular risk
factors, higher uric acid levels at baseline were found to be associated with later
decreased risk of dementia and better cognitive function.106
The conclusion from these population-based studies is that uric acid is probably
beneficial with respect to cognition at least in individuals without substantial
vascular risk factors. It is not known whether uric acid is only a secondary
marker of vascular disease in people with several vascular risk factors, such as
obesity, diabetes, hypertension and hypercholesterolaemia, as uric acid levels
are known to be increased in these states. An alternative explanation is that the
28
function of uric acid is altered in the vascular endothelium during
atherosclerosis. At the beginning of this process, uric acid has a major
contribution to the plasma antioxidant capacity. As atherosclerosis advances,
the pH of vascular endothelium and intima becomes acidic, local antioxidants
are depleted and ROS cause an ongoing oxidative stress. In this milieu, the
antioxidant properties of uric acid may change into pro-oxidant in a reaction
called antioxidant/pro-oxidant redox shuttle 107. This theory would be in
conjunction with epidemiological findings presented above.
In addition to our studies concerning uric acid and cognition in PD, there is only
one study exploring this subject. Moccia et al. recruited 80 patients with newly
diagnosed PD. The study subjects filled in a validated questionnaire
(NMSQuest) to detect non-motor symptoms of PD. The authors reported that
higher serum uric acid levels were associated with better attention and memory
at the early stages of the disease 108. At the follow-up evaluation, this
association remained strong; the patients with high serum uric acid levels
reported fewer problems in the attention and memory domain of NMSQuest 109.
The obvious limitation of this study was the lack of a neuropsychological
examination.
While the findings of Moccia et al. seem promising, the role of uric acid in
neurocognitive changes in PD remains unresolved.
Event-related potential findings in PD
Event-related potentials (ERPs) during electroencephalogram (EEG) recording
are used to detect visual or auditory information processing in the brain110.  The
focus of this review is on the auditory modality.
An ERP is a cortical response time locked to a sensory stimulus or a mental
occurrence presented during EEG recording. The stimuli can be expected by the
patient, who is advised to focus on certain kinds of sounds (target) and to ignore
others (standard or non-target). An unexpected and often strange sound is called
a novel stimulus or novelty.  ERP contains positive and negative waves that are
named according to their latency and polarity. N100 is a negative response that
occurs approximately 100 ms after the stimulus, and P200 is a positive response
that occurs approximately 200 ms after the stimulus. ERPs can be used to
examine attention, memory and language111.
A non-target sound usually elicits N100 and P200 responses, indicating that the
stimulus has been noted. The N100 describes activity of both auditory and
frontal cortices112 and correlates with attention and also with filtering out
irrelevant information; once noted, a standard tone does not require further
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cognitive processing and can be forgotten113. The magnitude of the N100
response also declines upon repetition of the stimulus, a phenomenon called
habituation114.
A target sound elicits a N200-P300b complex, reflecting conscious stimulus
processing in the brain. A novel surprise sound causes a larger and earlier P300a
wave that is considered to describe an orienting response to a new situation and
ensuing cognitive processing111.
The P300 component of EEG-ERP is considered most sensitive to detect
cognitive impairment in various patient populations, and it is also the most
extensively studied in PD.  The latency of the P300 response has been reported
to be prolonged in PD,115 and especially in PD-MCI and PDD, where the
response is often absent altogether. These findings are very consistent, but
similar findings have been described in amnestic MCI and AD, thus reducing
the specificity of P300 in detecting PD-related cognitive impairment.
N100 and P200 potentials have gained less research interest in PD, and the
findings have been inconsistent. Both the N100 and P200 latencies have been
measured as normal118-120 or prolonged114,121-123 in PD. The only previous study
comparing the N100 potential and neuropsychological examination was
conducted by Raudino et al.,123 who failed to show an association.
An explanation for these inconsistencies may be methodological variation and a
limited number of study subjects. Also the patient populations described have
been quite heterogeneous concerning age as well as severity and duration of the
disease.
What makes the N100 potential an intriguing research subject in PD is its role in
describing attentive processes87,113,124. Attention is not just a simple reaction, but
a complex, partly subconscious process that has developed to enable tracking of
relevant sensory information and ignoring irrelevancies. Being able to sustain
attention also contributes to working memory by preventing redundant stimuli
being processed and stored even temporarily.  Attention is under the control of
the basal ganglia and often impaired early in the course of PD125. Attentional
impairment may therefore also partly explain the poor working memory often
noted in early PD126,127
Although EEG-ERP measurements would provide objective information on the
stimulus processing in the brain, there are no clinical applications to aid in the
diagnosis of neurodegenerative diseases. The inconsistent results from previous
studies and rather low specificity for PD have probably hindered willingness to
develop this method in clinical practice. However, there are certain practical
aspects of EEG-ERP that might make it beneficial in PD populations.  EEG-
ERP does not require any physical effort from the patient; PD patients usually
suffer from slowness of movement and poor manual dexterity. EEG-ERPs are
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non-invasive, relatively easy to measure and inexpensive compared with a
neuropsychological examination, which patients often consider exhaustive.
Test-retest reliability is good,128 and especially the N100 potential and to some
extent also P200 seem to be independent of age128,129. The role of N100 as a
sensory gatekeeper links it to the neuropsychological defects that are common
in PD.  Essential for future studies would be to select more homogeneous
patient populations concerning especially the duration and severity of the
disease.
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Aims of the study
This thesis consists of four studies, which are later referred to as Studies I, II, III
and IV.
Study I was conducted to examine whether uric acid, considered both an
antioxidant and an iron binding molecule and having neurocognitive properties
in experimental studies, is diminished in the plasma or urine of PD patients
compared with normal controls.
Study II aimed to determine whether an association exists between plasma/urine
uric acid level and cognitive changes in non-demented PD patients.
Study III aimed to examine whether a low level of plasma/urine uric acid would
predict faster cognitive decline in PD after 3 years of follow-up.
Study IV aimed to examine the usefulness of neurophysiological measurements
in evaluating cognition in PD and whether uric acid levels are associated with
the neurophysiological parameters measured.
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Description of Studies I-IV
Studies I-IV are prospective studies including PD patients from the neurological
outpatient clinic of Jorvi Hospital.
Inclusion criteria for Studies I-III were idiopathic PD as defined in the UK
Parkinson’s disease Brain Bank clinical diagnostic criteria, age 50-70 years and
disease duration from diagnosis of no more than 10 years. The control group
was formed by patients’ spouses, who were age-matched and had no history of
PD. Exclusion criteria for both the patients and controls were current use of
medications affecting plasma uric levels, current iron metabolic disorder,
dementia and refusal to participate.
For Study IV, the inclusion criteria were idiopathic PD as defined in the UK
Parkinson’s disease Brain Bank clinical diagnostic criteria and no clinical signs
of dementia. The exclusion criterion for patients was current use of a
medication other than levodopa that affects plasma uric acid levels. The controls
were healthy volunteers for whom the inclusion criterion was a normal result in
the Consortium to establish Alzheimer’s disease (Cerad) test series to exclude
mild cognitive impairment and dementia, and the exclusion criterion was any
clinical sign of neurological disease.
Studies I-IV were approved by the Ethics Committee of the Health District of
Helsinki and Uusimaa. All patients and controls signed a written informed
consent form.
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Study I
Materials and Methods
Study I was planned to include 40 PD patients and their eligible spouses, whom
we were able to recruit during a 9-month period starting in February 2005. In
the patient group, the mean disease duration from diagnosis was 4.1 years and
the mean motor UPDRS score was 18.8 points (range 5-35). All patients were
on medication; 28 on levodopa with a median daily dose of 415 mg, 28 on
dopamine agonist and 31 on selegiline. Levodopa equivalent daily dose values
were not calculated.
Fasting blood samples were collected from both patients and controls to assess
the levels of uric acid, ferritin, transferrin, transferrin saturation, transferrin
receptor, iron, haemoglobin, ceruloplasmin and creatinine. All urine excreted
over 24 hours was collected to analyse urine uric acid concentration.
As dietary factors are known to affect plasma uric acid levels, a dietary recall
diary was kept for 4 days to control for this confounder. Also weight affects
plasma uric acid levels, and therefore, weight was measured and the patients
and controls reported their height to calculate body mass index (BMI). The
demographic characteristics and laboratory findings are presented in Table 1.
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Table 1.
Demographic characteristics and laboratory findings of patients and controls.
  Study group n=40  Control group
n=29
   Reference range
Mean age, years (SD)    60.8 (6.5)    60.2 (5.1)
Sex, men (%)    58    45
MMSE score, mean
(range)
   28 (25-30)    28 (23-30)
Hypertension, prevalence
(%)
   28%    17%
Smoking, prevalence (%)    8%    0%
Plasma uric acid, umol/l    278.5 (77.4)*    319.7 (76.0)*
  155-400
(women)
  230-480 (men)
Urine uric acid, umol/l    3.2 (1.1)**    3.5 (1.1)   3-6
Creatinine, umol/l, mean
(SD)
   71 (12.4)    70 (11.3)   58-100
Haemoglobin, g/l    141.4 (11.6)    144.8 (9.4)   117-167
Ferritin, ug/l    84.6 (62.3)    91.1 (83.0)   5-200
Transferrin, g/l    2.6 (0.4)    2.5 (0.3)   1.75-3.13
Transferrin saturation, %    27.8 (9.4)    32.0 (10.2)   17-52
Transferrin receptor, mg/l    1.2 (0.5)    1.1 (0.3)   0.9-2.3
Iron, umol/l    18.2 (5.5)    20.5 (6.3)   9-34
Ceruloplasmin, mg/l    310.3 (46.8)    301.1 (68.8)   200-550
Means, standard deviation in parentheses.
* T-test: p=0.03, inter-assay variation 2.8-3.4%
** n=37
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Results
The main finding of Study I was that PD patients had significantly lower levels
of plasma uric acid levels than controls. The finding was not explained by
differences in dietary patterns or BMI. Based on the dietary recall diaries, the
patients and controls consumed similar amounts of calories, fats, carbohydrates,
proteins, cholesterol, vitamins A, B12, C, D and E; also the amounts of iron,
zinc and selenium were similar.
BMI was lower in patients than in controls, and this finding was of borderline
significance (T-test, P=0.05). Expectedly, BMI correlated strongly with plasma
uric levels in both the patient and control groups. To control for BMI and other
factors possibly confounding the results regarding uric acid levels, a stepwise
multiple linear regression was used. Age, gender, BMI, ferritin and PD were all
found to contribute significantly to plasma uric acid level (p=0.0001 for the
model).
No differences emerged between patients and controls in the markers of
peripheral iron metabolism.  Plasma uric acid level showed a strong correlation
with serum ferritin level (r=0.52, p=0.001).
Study II
Materials and Methods
In Study II, the same patient population as in Study I underwent a thorough
neuropsychological examination. The tests were chosen from the Wechsler
Adult Intelligence Scale, Revised, Wechsler Memory Scale, Third Edition and
Behavioral Assessment of the Dysexecutive syndrome to assess visual and
verbal working memory, visuospatial and visuoconstructive abilities, verbal
fluency and executive functions. Mood was evaluated with Beck Depression
Inventory (BDI).
In addition to the traditional neuropsychological tests, computerized tasks with
Cognispeed software were used. Cognispeed was developed in Finland to be
used in both linical and research settings to examine certain aspects of
cognition. The testing situation is assisted by a psychologist familiar with the
software. One of the central aims of Cognispeed is to differentiate between
automatic and controlled information processing. The tasks are planned to
measure speed and span of working memory and the time to make the
appropriate decision in multiple choice situations. It also examines different
aspects of attention such as dividing attention between simultaneous memory
and decision tasks, concentrating attention in the subtraction task, suppressing
redundant information in the Stroop type task and being able to sustain and
focus attention on a certain stimulus and reject others in a vigilance task lasting
15 minutes. Considering the attentional and working memory problems often
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detected in PD, Cognispeed was considered a valuable addition to the traditional
neuropsychological examination in our patient sample.
Results
The main finding of Study II was the correlations of both urine and plasma uric
acid levels with several cognitive measures as shown in Table 2.
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Table 2.
Correlations of urine- and plasma uric acid with neuropsychological tests
Test
Pearson
Correlation
with urine uric
acid
Pearson
Correlation
with plasma
uric acid
General cognitive
status
MMSE
Information 0.37
Similarities 0.40 0.36
Visual functions
Block design 0.41
Picture completion 0.46 0.37
Learning and
memory
Digit span forward
Digit span backward  0.33
Digit symbol
Logical memory
Word list
Visual reproduction
Executive functions
Trail making A
Rule shift cards  0.34 0.09
Verbal fluency
Animals  0.10
Words with K -0.21
Cognispeed
SRT
2-CRT
10-CRT -0.32
Subtraction
Statement
verification
-0.58 -0.38
Cognitive processing -0.58 -0.37
Stroop type task
Vigilance (n=34) -0.44 -0.41
Only the significant correlations with p<0.05 are shown
MMSE=Mini mental state examination
SRT= Simple reaction time
2-CRT= 2-choice reaction time; 10-CRT=10-choice reaction time
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To control for possible confounding factors that might also contribute to
cognitive performance, a multiple linear regression was used. The possible
confounders taken into account in the analysis were age, gender, disease
duration from diagnosis, plasma homocysteine, depression, education, levodopa
therapy and BMI.
In the multiple regression analysis, urine uric acid was the only variable that
predicted both reaction time and time spent on cognitive processing in the
Statement verification task
(F = 16.5, R2 = 0.31, p = 0.0001; F = 17.3, R2 = 0.33, p = 0.0001, respectively)
as well as achievement in the Picture Completion test
(F = 10.1, R2 = 0.21, p = 0.003). Urine uric acid also had a small but significant
contribution to the Rule shift cards and Block Design scores. Education, gender
and depression accounted for some of the variation observed in the
neuropsychological parameters.
Also plasma uric acid was found to be associated with the Statement
verification task together with education (F = 6.2, R2 = 0.26, p = 0.005 for
reaction time and F = 7.6, R2 = 0.3, p = 0.002 for time required for cognitive
processing during the task). Plasma uric acid and education contributed to the
Similarities subtest (F = 5.7, R2 = 0.24, p = 0.007).
In summary, both urine and plasma uric acid seemed to have small but
significant effects on the speed of cognitive processing as well as on
achievement in the tasks requiring visuoconstructive abilities and visual
memory.
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Study III
Material and Methods
After three years of follow-up, the same research protocol was repeated in
Study III. Neuropsychological evaluation was performed on patients and both
patients and controls underwent laboratory testing and completed a 4-day
dietary recall diary. As a novel feature, the computerized tasks with Cognispeed
were performed on both patients and controls.  Unfortunately, several patients
were lost to follow-up for reasons other than PD, and only 28 patients and 13
spouse controls were examined.
Results
There was no significant change in plasma or urine uric acid levels during
follow-up. BMI and eating habits also remained stable. Surprisingly, there were
only minor cognitive changes in the patient group. A significant deterioration
was noted in Verbal fluency (p=0.04) and Cognispeed’s vigilance task
(p=0.0001). No significant change occurred in Cognispeed’s statement
verification task, but the time required for cognitive processing during the task
was lengthened (p = 0.03).
 When patient data on Cognispeed were compared with control data, a
significant difference was present in Stroop-type colour-word reading task
(p=0.05), delayed visual reproduction task of WMS-R (p=0.01) and both simple
and two-choice reaction times (p = 0.03 and p = 0.004, respectively).
After controlling for possible confounding factors, such as age, gender,
education, disease duration from diagnosis and BDI, with forward linear
regression, only the baseline urine uric acid seemed to contribute to
neuropsychological performance. It was associated with verbal fluency
(R2 = 0.15, F = 4.6, p = 0.04), picture completion
(R2 = 0.35, F = 13.9, p = 0.001), block design (R2 = 0.28, F = 10.0, p = 0.004),
vigilance (R2 = 0.27, F = 9.7, p = 0.004), subtraction
(R2 = 0.23, F = 7.5, p = 0.01) and statement verification
(R2 = 0.28, F = 10.0, p = 0.004) tasks.  The correlations of the baseline plasma
and follow-up plasma and urine uric acid levels with cognition seemed non-
significant.
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Study IV
Materials and Methods
For Study IV, we recruited 14 patients from the above-described patient
population and, due to dropouts in the primary sample, 4 additional patients
from the neurological outpatient clinic of Jorvi Hospital. The controls were
members of the hospital staff and their acquaintances.
For this final study, 18 patients and 24 controls underwent EEG-ERP
measurement. Recording and quantification of EEG and stimuli to induce ERP
were done with a Cognitrace EEG/ERP system, version 3.3.
During the ERP recording the patients were asked to follow a silent nature
movie shown on a TV screen at a distance of 1.5 metres. Auditory stimuli were
given through calibrated headphones (Telephonics TDH-39P), and the patients
were instructed not to pay attention to the tones. The auditory ERPs were
stimulated with pairs of tones with an inter-stimulus interval (ISI) of 0.5 and 3
seconds, as well as novelty sounds. The responses to first and second tones of
pairs with 0.5 second ISI were analysed. ERP responses for 40 pairs of stimuli
were averaged.
The amplitude and latency of N100 (Cz) and P200 (Cz) elicited by the auditory
stimuli were measured with respect to the highest negativity in a 60-170 ms
post-stimulus time interval and the highest positivity in a 100-260 ms interval.
Habituation of the N100 was calculated as the difference between the
amplitudes elicited by the first and second tones of a pair with 0.5 second ISI.
Neuropsychological data from the previous study were available for 15 patients
and the plasma uric acid measurement for 16 patients. The Consortium to
establish Alzheimer’s disease (Cerad) test series was conducted for controls to
rule out cognitive decline; a normal result was required for the subject to be
included in the control group.
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Results
Demographic characteristics of patients and controls as well as latencies and
amplitudes of the N100 and P200 potentials are presented in Table 3.
Table 3.
PD patients (n=18) Controls (n=24)
Age (range) 62 (42-71) 67 (60-79)
Gender , % of males 44% 33%
MMSE (range) 28 (23-30) 28 (28-30)
Duration of disease in years,
mean (range)
6 (2-13)
UPDRS-motor, mean (range) 17 (1-51)
Levodopa usage 13
Levodopa dose, mean (range) 425 mg (250-875mg)
Dopamine agonist 12
Selegiline 13
N100 Latency, mean (SD) 107.6 ms (23.2)* 95.1 ms (16.6)*
N100 Amplitude, mean (SD) -5.5 uV (2.0) -5.3 uV (2.0)
P200 Latency, mean (SD) 208.5 ms (30.7) 214.6 ms (21.5)
P200 Amplitude, mean (SD) 5.3 uV (2.8) 4.3 uV (1.7)
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The N100 latency was significantly prolonged in patients relative to controls
(Mann-Whitney test, p=0.005). With visual assessment, the change in the N100
amplitude between responses to the first and second tones of a pair of tones,
called habituation, was more pronounced in controls than in patients, although
this difference did not reach statistical significance. The grand averages of
patients and controls are shown in the picture.
Prolongation of the N100 latency and reduced habituation of the N100
amplitude were associated with the delayed visual reproduction task of the
WMS-R (Spearman rank -0.62, p=0.001).  The patients were further divided
into two groups according to the median score of this neuropsychological test
result. The patients with an above median result had shorter N100 latencies
(Mann-Whitney p=0.007) and stronger habituation of the N100 amplitude
(Mann-Whitney p=0.004).
No correlation existed between N100 latency or amplitude habituation and
plasma uric acid level in the patients.
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Discussion of Studies I-IV
In Study I, we were able to show that PD patients had lower levels of plasma
uric acid than normal controls. This finding remained significant after carefully
controlling for several possible confounding factors. Of the confounders, BMI
was lower in patients than in controls, and this finding was of borderline
significance (p=0.05). Plasma uric acid level correlates with BMI, and it cannot
be excluded that this difference in BMI might have had an effect on the results.
In that case, low uric acid level might only be a secondary marker of the weight
loss commonly seen in PD, especially in the more advanced stages.
Considering that the patients and controls had similar dietary patterns and
energy intakes, the lower BMI in the patients may also reflect gastrointestinal
dysfunction and malabsorption of nutrients. Previous studies have shown that
PD patients’ energy intake is high and expenditure low, indicating that the
patients are incapable of exploiting all energy consumed.  It is also possible that
some important nutrients, such as purines needed to produce uric acid, are
malabsorbed in PD, or that the altered microbiome and intestinal inflammation
accelerate the degradation of uric acid in the intestine, as suggested by
Scheperjans et al. In that case, the disease-related pathology in the intestine
would at least partially explain the low plasma uric acid levels in the patients.
Two studies have confirmed our results concerning plasma uric acid levels in
PD130,131. They have both found a strong correlation between plasma uric acid
levels and disease duration, which we did not take into account in the statistical
analysis. This finding also points towards low plasma uric acid level being
partially a consequence of the disease or perhaps the medication (levodopa), as
suggested by the authors. Levodopa increases the secretion of uric acid by the
kidneys. Considering the expanding evidence for a neuroprotective role of uric
acid in PD, the possibility that the disease itself or symptomatic medication, e.g.
levodopa, lowers plasma uric acid levels makes such therapeutic strategies as
using inosine to increase plasma uric acid levels even more justified.
In Study I, we found no difference in markers of peripheral iron metabolism
between patients and controls. According to the current knowledge, disorders of
peripheral iron metabolism are not related to PD. This does not exclude the
possibility of disturbed iron storage and transfer in the brain. In PD, there is an
increase in the amount of iron in the substantia nigra and malfunction of local
iron storage proteins such as neuromelanin. An excessive pool of unbound,
labile iron probably accelerates the neurodegenerative process by increasing
oxidative stress.
Our study could not resolve whether uric acid also has an impact on cognitive
decline in PD. In Study II, we found both plasma and urine uric acid to be
associated with cognition in PD. Interestingly, the associations concerned the
areas of cognition that are often disturbed in PD, namely verbal memory and
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speed of processing,  visuospatial and visuoconstructive skills and executive
function. The findings were so promising that they encouraged us to follow the
study sample for three more years, resulting in Study III. Surprisingly, at the
end of the follow-up, there was no significant deterioration in the cognitive
profiles of the patients. Of the neuropsychological parameters, only verbal
fluency, vigilance and speed of cognitive processing were significantly impaired
relative to baseline evaluation. The computerized tasks were performed by both
patients and controls; the only differences between the two groups were in
Stroop-type colour-word reading task, delayed visual memory and reaction
times.
In summary, the patients had subtle cognitive alteration typical for PD and some
progression over the three-year follow-up. However, with respect to disease
duration, they were indeed cognitively very well preserved. Cognitive defects or
their progression did not seem strongly related to either baseline or current
plasma or urine uric acid levels. The relative stability of neurocognitive
symptoms in patients and the small sample size were also major obstacles in
determining uric acid’s possible protective effect on cognition.
The results of Study III may be partly explained by a chance selection bias; the
patient population was largely formed by individuals with high socioeconomic
status and educational level and with lifestyle factors contributing to the
preservation of cognition 132. Their cognitive reserve probably protected them
from the somewhat faster cognitive decline usually observed in PD. Although
we aimed to recruit consecutive patients, it is possible that the ones with more
severe cognitive or neuropsychiatric symptoms declined to participate. Our
patient sample may therefore not be fully representative of all PD patients.
 The patients also visited a neurologist regularly and were advised to remain
physically active, to avoid weight loss and to consume a protein-rich diet
despite the limitations caused by levodopa medication.  These actions decrease
the likelihood of both cognitive decline and reduction in plasma uric acid levels.
Gender probably also had an effect. At the time of Study III, it was not yet
established that the neuroprotective effect of uric acid is more pronounced in
men than in women, in whom it may actually be non-existent133,134. To show
uric acid’s association with cognition in PD would therefore require a larger
number of study subjects to be adequately powered or alternatively a study
recruiting only male patients. Unfortunately, we also lost several patients to
follow-up, which may have affected the results in such a small patient sample.
Uric acid’s possible effect on cognition may also have been confounded by the
variation in disease duration in our patient sample. In future studies, it would be
important to recruit patients at similar disease stages and preferably already at
the time of diagnosis.
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The findings in healthy populations regarding uric acid’s detrimental effect on
cognition also warrant consideration. High serum uric acid level increases the
risk of cerebral vascular lesions, and this association seems independent of other
vascular risk factors such as hypertension, diabetes, smoking and obesity. Also
in PD there is increasing evidence of vascular risk factors and cerebral vascular
pathology contributing to cognitive decline and increasing the risk of PDD
135,136.  If uric acid gains pro-oxidant properties in atherosclerosis, its effect on
cognition may be detrimental in PD patients with considerable cerebrovascular
burden and neuroprotective in the ones with more classic PD-related brain
pathology. Discerning these PD patient subpopulations in future studies will be
a laborious undertaking, but probably necessary to disclose uric acid’s true role
in the cognitive decline of PD. Underlying vascular pathology may also be an
unrecognized confounder in our study since we did not perform neuroimaging
on our patients. However, vascular risk factors were rather uncommon; of the
original 40 patients, 8 had a history of hypertension, 3 were current smokers and
1 had diabetes.
In Study IV, we found an interesting association of visual working memory
with N100 latency prolongation and diminished amplitude habituation. This
finding opens a window into the PD brain, shedding light on the interplay
between attention, visual function and working memory or more accurately on
the network between basal ganglia and frontal and occipital cortices. The
heterogeneous mechanisms of cognitive decline and the large individual
variation in both brain pathology and clinical picture of PD-MCI and PDD
hinder the development of EEG-ERP for clinical use. However, the same
problem concerns other biomarkers, such as MRI, PET and SPECT, the findings
of which are not always in line with the individual clinical picture. Obvious
limitations of Study IV were the small sample size and the large variation in
disease duration.
Study IV was designed as a pilot and in that respect the results were promising
considering the association of N100 potential with visual working memory. To
develop a diagnostic tool to assess cognitive decline in PD would again require
a larger number of patients in a similar disease stage. A clinical application
might facilitate identification of PD patients at risk of cognitive decline even in
the absence of cognitive symptoms or neuroimaging findings of cerebral
vascular pathology. Identifying these patients might help in guiding treatment
decisions such as initiating inosine to increase plasma uric levels.
In Study IV, we found no correlation between measured EEG-ERP parameters
and uric acid. In light of the results of Study III, this was an expected finding.
To show an association with a neurophysiological parameter measuring a
narrow area of cognition would require a very strong association of uric acid
with cognition, and this does not seem to be the case. Uric acid is more likely a
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modifier of the risk of cognitive decline in PD, one of many whose combination
in the end is decisive in determining the rate of cognitive decline at the
individual level.
The first submission of Study IV to the Journal on Neural Transmission also
included data on uric acid, but the reviewers did not find this interesting and it
was therefore excluded from the final publication.
The main strength of our studies is that patients had a good diagnostic accuracy
concerning the diagnosis of PD and the evaluation was extensive with UPDRS
and Hoehn and Yahr staging and both laboratory and neuropsychological
testing. To date, Studies II and III are the only ones to examine the effect of uric
acid on cognition in PD in a longitudinal setting with repeated
neuropsychological testing. The laborious and expensive protocol explains the
small sample size and also the lack of similar studies. Despite the small sample
size, Study II found that low plasma and urine uric acid levels were associated
with deterioration in the areas of cognition that are most vulnerable in PD and
which often precede the development of PDD. That the plasma uric acid levels
and cognition did not significantly change during follow-up may reflect the
presence of several confounders in a small patient sample. At the end of the
follow-up, it was not possible to reliably evaluate the prognostic value of
plasma uric acid level on the rate of cognitive decline in PD. Our studies as well
as others’ point to low plasma uric acid level being a long-term condition
predisposing to PD and faster progression of both motor and cognitive
symptoms in PD.  Whether the main determinant of plasma uric acid level is
genetic, dietary or related to possible gastrointestinal pathology in PD remains
unresolved.
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Suggestions for future studies
The size of Study I was quite small, but allowed for a careful exclusion of the
confounding factors.  However, a larger study to verify the result is justifiable
and might be possible with the advent of biobanks. The Helsinki Biobank could
offer a plasma uric acid sample of all PD patients in the Hospital District of
Helsinki and Uusimaa as well as samples of age- and gender-matched controls.
This method would provide a large unselected sample of PD patients, although
confounders, such as medication and dietary patterns, could not be evaluated.
To guide future studies on the postulated association between uric acid and
cognition, I suggest that patients be recruited already at diagnosis. This would
ensure that patients are at similar disease stages and more comparable and also
would minimize changes in plasma uric levels during the course of the disease.
The patient sample should be large enough to enable statistical analysis
separately for males and females because the neuroprotective effect of uric acid
may differ by gender. Also vascular risk factors should be evaluated, with
laboratory testing of serum cholesterol and fasting glucose levels, history of
hypertension and family history of cerebro- and cardiovascular diseases.
Neuroimaging would also be mandatory to show existing vascular pathology.
A disease-modifying treatment, inosine, may become available in the near
future. Prior to this, it would be important to gain more knowledge of uric acid’s
effect on cognition in PD. The fact that uric acid may be protective in some
conditions and detrimental in others makes careful patient selection a critical
feature in any treatment aiming to increase plasma uric acid levels.
Fortunately, one study has already been initiated in Spain called the Coppadis
(Cohort of patients with Parkinson’s disease in Spain 2015)137. This study aims
to recruit 800 PD patients who will be followed for five years to examine the
natural course and various aspects of the disease, including motor and non-
motor symptoms, pain, neuropsychiatric symptoms, mood disorders and their
impact on the quality of life of both patients and caregivers.
A subgroup of 300 patients will be selected to investigate also biomarkers,
including serum uric acid and MRI of the brain. The study protocol does not
include neuropsychological examination, but all patients will be tested with
MMSE and Parkinson’s disease cognitive rating scale and will have to complete
a 16-piece puzzle. In my opinion, this study will provide key new data
concerning the association of uric acid with cognition in PD.
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